Peptides for Reference

4 research peptides are currently studied for reference. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

Human growth hormone (hGH), also known as somatotropin, is a 191-amino acid peptide secreted by the anterior pituitary gland. Its clinical utility is well-documented, particularly in the management of growth hormone deficiency in both children and adults. Research indicates that hGH therapy can significantly improve growth rates in pediatric patients and enhance muscle mass and metabolic function in adults with growth hormone deficiency. The FDA has approved hGH for specific indications, underscoring its established role in clinical practice. However, potential side effects, including edema, joint pain, and metabolic disturbances, necessitate careful patient monitoring. Studies also highlight the importance of individual response variability, emphasizing that while hGH can provide substantial benefits, its use must be tailored to the specific needs of the patient.

Insulin-like Growth Factor 1 (IGF-1) is a 70-amino acid peptide that plays a crucial role in mediating the effects of growth hormone. Produced predominantly in the liver, IGF-1 is essential for growth and metabolic processes throughout life. The FDA has approved IGF-1 for the treatment of severe primary IGF-1 deficiency in children, demonstrating its significance in pediatric endocrinology. Research indicates that IGF-1 promotes muscle growth and development, influencing cellular proliferation and differentiation. However, while its therapeutic potential is well-supported, the safety profile includes risks such as hypoglycemia and potential tumor growth in certain contexts. Ongoing studies continue to explore IGF-1's broader implications in metabolic disorders and muscle-wasting conditions, although the intricacies of its signaling pathways warrant careful consideration in clinical applications.

Endothelin-1 — Well-Characterized / ERA Drugs Approved

Endothelin-1 (ET-1) is a 21-amino-acid peptide recognized as the most potent endogenous vasoconstrictor. It is predominantly produced by vascular endothelial cells and plays a critical role in regulating vascular tone and blood pressure. The endothelin pathway has been implicated in various cardiovascular diseases, particularly pulmonary arterial hypertension (PAH), where ET-1 contributes to pathophysiological changes leading to vascular remodeling and increased pulmonary arterial pressure. Several endothelin receptor antagonists (ERAs) have received FDA approval for the treatment of PAH, demonstrating the clinical relevance of targeting this pathway. While ET-1's vasoconstrictive properties are well-established, research indicates that excessive ET-1 signaling can lead to adverse cardiovascular outcomes, necessitating a balanced understanding of its role in health and disease. Ongoing investigations aim to further clarify the therapeutic potential of modulating ET-1 activity in various vascular disorders.